Please login to the form below

Not currently logged in
Email:
Password:

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

JJ

Johnson & Johnson’s oral multiple sclerosis (MS) therapy ponesimod outperformed Sanofi blockbuster Aubagio in a phase 3 comparative trial, setting up regulatory filings and a possible approval next year.

Ponesimod, a S1P receptor modulator acquired as part of J&J’s $30bn acquisition of Actelion in 2017, achieved a statistically significant 30.5% reduction in the annualised relapse rate (ARR) compared to Aubagio (teriflunomide) in patients with the relapsing form of MS.

J&J said in July that the trial had hit its primary endpoints and most of the secondary outcome measures in the trial – called OPTIMUM – but has just presented the actual data at the ECTRIMS conference in Stockholm.

Ponesimod also did significantly better than Sanofi’s drug on fatigue scores, MRI assessments of the number of active lesions in the brain, and the time to confirmed disability accumulation (CDA), a measure of disease progression.

J&J says it now intends to move ahead with marketing applications for ponesimod in the US and Europe and – if approved – it will be the first direct rival to Novartis’ S1P receptor modulator franchise based on Gilenya (fingolimod) and recently-launched follow-up Mayzent (siponimod), which for now is approved for secondary progressive forms of MS only.

Revenue prospects for ponesimid are tough to predict, as it is entering an increasingly crowded market for MS therapies, with a range of blockbuster oral therapies already available including Biogen’s market-leading Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab) also making strong headway in the market.

Also coming through the pipeline is Biogen’s Tecfidera follow-up diroximel fumarate (BIIB098), Novartis’ new antibody ofatumumab, and Celgene’s S1P receptor modulator ozanimod that is due for regulatory decision in the US and Europe next year.

J&J doesn’t have a strong heritage in MS, which could make it tougher to build market share. The company does however have a resurgent central nervous system (CNS) therapeutic category following the approval of Spravato (esketamine), a nasal spray for treatment-resistant depression that J&J reckons can become a $1bn product.

There is also a looming threat of generic competition to Gilenya and Tecfidera, which could make it harder for new drugs to negotiate access with payers. So far Novartis and Biogen have been able to defend their patents on the drugs, but legal challenges continue.

Article by
Phil Taylor

12th September 2019

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....